India Pesticides Targets INR 3,000 Crores by FY31

India Pesticides Limited — Q4 FY26 Earnings Conference Call (25 May 2026)

1. Overall Tone of Management: Optimistic

• Management repeatedly emphasizes “strong execution,” “improving market conditions,” “well positioned to sustain growth momentum,” and “remain optimistic.”
• They also reaffirm long-term targets with confidence: “we are very much intact” on the INR 3,000 crores by March 2031 plan.

2. Key Themes from Management Commentary

• Strong FY26 financial performance and margin expansion
• Revenue crossed INR 1,000 crores for the first time; EBITDA margin improved to 18% (from 15.9% in FY25).
• Demand normalization + China Plus One sourcing tailwind
• “Channel inventories normalize” and customers prioritize “dependable and diversified sourcing partners.”
• India emerging as a preferred sourcing destination under China Plus One.
• Backward integration driving resilience and cost competitiveness
• Hamirpur facility progress; commissioning of an intermediate plant using in-house indigenous R&D.
• PEDA/Pretilachlor capacity expansion supports supply stability and import reduction.
• Formulations scaling and distribution build-out
• Formulation capacity scaled to 10,000 metric tonnes, with 18 states / 24 depots.
• Export remains meaningful despite pricing/geopolitical disruptions
• Exports ~39% of FY26 revenue, with temporary pricing challenges attributed to geopolitics.
• Forward-looking capex funded largely by internal accruals
• FY27 capex: INR 45 crores (standalone); INR 90 crores (subsidiary); funding mainly via internal accruals.

3. Q&A Analysis

Theme A: Pricing power, cost pass-through, and demand drivers

• Core questions
• What price increases were taken (pre/post March) and whether demand strength is due to inventory run-down or China price hikes.
• Whether sulphur-based products are driving higher pricing.
• Management response
• China prices rising: “China is also increasing prices… prices are slightly changing on a daily basis.”
• They claim successful cost pass-through: “we have tried to pass on the cost differential… and we have been successful.”
• No clear portfolio-wide % increase given; they note variability by raw material: “difficult to tell… some products… increased slightly more.”
• Evasive/partial
• Analyst asked for average % price increase; management did not provide a number and instead gave qualitative detail.

Theme B: Contribution and ramp-up of new facilities/products (Shalvis, PEDA/Pretilachlor, Hamirpur)

• Core questions
• How much of the 30% volume growth came from new blocks (Shalvis) and PEDA/Pretilachlor.
• FY27 expectations for PEDA/Pretilachlor and Shalvis ramp-up; timing of second Shalvis block.
• Management response
• Shalvis contribution: INR 4–5 crores revenue in FY26.
• PEDA/Pretilachlor: capacity utilization expected 70%–75% (seasonal shutdown ~3 months, typically Aug–Oct).
• FY27: PEDA/Pretilachlor expected to be better because capacity commissioned in March: “we will be utilizing the full capacity… so this year also will be better.”
• Shalvis FY27 revenue guidance: INR 70–80 crores including the new block; second block expected Sep/Oct 2026.
• Notable strength
• They provided specific revenue ranges for Shalvis and utilization assumptions for seasonal products.

Theme C: Margin outlook and working capital dynamics

• Core questions
• Expected EBITDA margin next year and working capital cycle impact.
• Whether higher inventory is needed due to spot buying vs quarterly planning.
• Management response
• Margin guidance: EBITDA 18%–20%.
• Working capital: net working capital days improved to 223 days; possible further improvement by 10–12 days by FY27.
• Inventory rationale: customers now buying “on a spot basis… we have to keep inventory slightly at a higher level.”
• Credibility note
• Margin guidance is consistent with prior calls (18–20%), but working capital improvement is constrained by customer buying behavior.

Theme D: FY31 revenue target credibility (INR 3,000 crores) and ramp math

• Core questions
• Are they intact with INR 3,000 crores by FY31 (and whether rainfall affects it).
• Roadmap split: existing plants vs Hamirpur/Shalvis; what peak capacity contributes.
• Management response
• Rainfall: they say they’re “very much intact” and expect production not to be materially impacted unless rainfall is “very diverse and very scattered.”
• Roadmap split (explicit):
  • Shalvis total revenue by March 2031: ~INR 1,000 crores
  • Existing plants + formulation facilities: ~INR 2,000 crores (Dewa Road, Sandila, formulation)
• FY27 revenue growth expectation: 15%–20%; EBITDA margin 18% holds good.
• No evasiveness
• They gave a clear split and reaffirmed the target.

Theme E: Competitive landscape and sustainability of margins (especially PEDA/Pretilachlor)

• Core questions
• With more producers likely entering, will margins hold?
• Management response
• “margins would be more or less same” and they frame it as a volume-driven game.
• They acknowledge PEDA/Pretilachlor margins are slightly lower than overall average but expect maintenance.

Theme F: Supply chain/geopolitical insulation

• Core questions
• How insulated are they from severe supply chain disruptions?
• Management response
• They cite long-term supplier arrangements and continuous local supply at “slightly higher price.”
• They claim critical raw materials are already arranged and expect ability to manage in the coming quarter.

4. Guidance / Outlook

Explicit guidance (quantitative)

• FY27 capex
• INR 45 crores (India Pesticides standalone)
• INR 90 crores (100% subsidiary)
• Funding: mainly internal accruals; “may take a small loan” in subsidiary.
• FY27 margin
• EBITDA margin: 18%–20%
• FY27 revenue growth
• Revenue increase: ~15%–20% (also referenced as “earlier guidance”)
• Shalvis / new block revenue
• Shalvis FY27 revenue: INR 70–80 crores (including second block assumed operational by Sep/Oct)
• PEDA/Pretilachlor utilization
• 70%–75% utilization (seasonal shutdown ~3 months, Aug–Oct)
• Working capital
• Net working capital days: 223 days in FY26, potential improvement 10–12 days less by FY27
• Long-term target
• INR 3,000 crores revenue by March 2031 (reaffirmed as “intact”)

Implicit signals (qualitative)

• Demand is “okay” and they expect no major demand issue.
• They believe pricing can be maintained despite RM/freight inflation due to:
• customer discussions and cost pass-through success
• backward integration improving cost competitiveness
• Inventory levels may remain slightly higher due to spot buying.

5. Standout Statements (direct / highly revealing)

• Cost pass-through confidence (but no % disclosed):
• “we have tried to pass on the cost differential… and we have been successful”
• Demand resilience framing:
• “Demand is okay… There is not much of a variation in the price for these molecules.”
• Shalvis ramp specificity:
• “we expect Shalvis revenues to be in the range of at least INR 70 crores to INR 80 crores.”
• Margin guidance reiterated:
• “Our margin ranges we have projected 18% to 20% EBITDA margin.”
• Working capital constraint explained:
• “Earlier, they were giving us quarterly planning. Now they are buying on a spot basis. So we have to keep inventory slightly at a higher level.”
• Long-term target reaffirmation:
• “No, no. We are very much intact… plan to achieve this INR 3,000 crores by March 2031.”
• Supply chain insulation claim:
• “We have done some long-term arrangements with some of our suppliers… critical raw materials… already arranged.”

6. Red Flags / Positive Signals

Red flags
– Pricing transparency gap: asked for average portfolio price increase; management avoided giving a number.
– Inventory/working capital trade-off: they admit higher inventory due to spot buying—could pressure cash conversion if it persists.
– Seasonality assumptions: PEDA/Pretilachlor utilization depends on seasonal shutdown; execution risk remains if timing shifts.
– Paraquat ban question: they said no substitute but also “we have a doubt… we are not very sure”—suggests potential uncertainty in product gap response.

Positive signals
– Clear ramp economics for Shalvis (revenue ranges + timing).
– Consistent margin guidance (18–20%) across calls.
– Working capital improvement already achieved (223 days vs 254 days FY25).
– Explicit capex funding plan (internal accruals dominant).

7. Historical Comparison & Consistency Analysis (vs prior calls)

a. Change in Tone Over Time

• Current (Q4 FY26): More Optimistic
• Stronger emphasis on “improving market conditions” and “well positioned to sustain growth momentum.”
• More confident reaffirmation of long-term targets: “very much intact.”
• Prior calls (Q2/Q3 FY26): Optimistic but more cautious on execution timing
• Q3 FY26: emphasized recovery and progress; still framed some items as “expected” (e.g., scale-up timelines).
• Q2 FY26: confidence was high but tied to monsoon and export recovery.
• Shift driver: FY26 results already delivered strongly (INR 1,000 crores milestone), enabling more assertive forward narrative.

b. Tracking Past Commitments vs Outcomes

• Shalvis ramp expectations
• Prior (Q2 FY26): Shalvis expected ~INR 100 crores revenue next year.
• Current (Q4 FY26): Shalvis FY26 revenue only INR 4–5 crores, and FY27 INR 70–80 crores.
• Assessment: ⏳ Delayed / scaled down vs earlier “~INR 100 crores next year” framing (timing and magnitude both appear less than earlier implication).
• PEDA/Pretilachlor capacity commissioning timing
• Prior (Q3 FY26): PEDA/Pretilachlor capacity expansion operational “in this month only” (utilization >80% at that time).
• Current (Q4 FY26): utilization guidance 70%–75% due to seasonal shutdown (Aug–Oct).
• Assessment: ✅/⏳ Operationally consistent with seasonality; not a miss, but utilization guidance is more conservative now.
• INR 3,000 crores target
• Prior (Q2/Q3 FY26): roadmap toward INR 3,000 crores by FY30–31.
• Current: reaffirmed March 2031 and “intact.”
• Assessment: ✅ Reaffirmed; no evidence of slippage in target date, but ramp math is still dependent on Shalvis execution.

c. Narrative Shifts

• Exports vs domestic emphasis
• Earlier calls highlighted export recovery strongly (e.g., Q2: exports nearly doubled).
• Current call still supports exports but adds more emphasis on domestic Q4 surge and inventory normalization.
• Shalvis story becomes more specific but less “immediate”
• Earlier: Shalvis expected meaningful revenue “next year.”
• Current: Shalvis FY26 contribution is small; FY27 becomes the main ramp year with explicit ranges.
• Risk framing
• Current call more directly addresses geopolitical logistics disruptions and supply chain criticality, including supplier arrangements.

d. Consistency & Credibility Signals

• Medium credibility
• Positives: consistent margin band (18–20%) and repeated long-term target.
• Concerns: Shalvis revenue expectations appear to have moved (from “~INR 100 crores next year” narrative to INR 4–5 crores in FY26 and INR 70–80 crores in FY27).
• Management often provides qualitative confidence but sometimes avoids numeric detail (e.g., pricing % increase).

e. Evolution of Key Themes

• Demand
• Improving: from “recovery” (Q2/Q3) to “channel inventories normalize” (Q4).
• Margins
• Stable/Improving: EBITDA margin improved to 18% and guidance remains 18–20%.
• Expansion
• More concrete execution milestones now (Hamirpur blocks, intermediate plant, Shalvis second block timing).
• Geopolitics / supply chain
• Becomes more prominent in Q4: logistics disruptions and supplier arrangements are explicitly discussed.

f. Additional Insights (cross-period)

• Execution timing risk is implicitly rising for Shalvis
• The gap between earlier “next year” revenue expectations and actual FY26 contribution suggests ramp-up may be slower than initially communicated.
• Cash conversion may be structurally constrained
• Working capital days improved, but management now admits higher inventory due to spot buying—could cap further improvement even if profitability remains strong.